Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
- PMID: 34321854
- PMCID: PMC8291010
- DOI: 10.3748/wjg.v27.i25.3913
Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
Abstract
Background: Helicobacter pylori (H. pylori) is an important pathogen that can cause a variety of diseases. Yet, full eradication of H. pylori remains a significant challenge in clinical practice. H. pylori and other microbial communities have complex interactions in the unique gastric microecological environment. However, it is not clear whether the interactions have any effect on the therapeutic effect of H. pylori.
Aim: The aim was to investigate the characteristics of the gastric microbiota with H. pylori infection and the influence on the H. pylori eradication treatment.
Methods: Patients with H. pylori infection underwent gastroscopy and received treatment for eradication. The prescription included esomeprazole 20 mg bid, Livzon Dele 220 mg bid, amoxicillin 1000 mg bid, and clarithromycin 500 mg bid for 14 d. Patients who did not respond to treatment and failed eradication were compared with those who achieved eradication by 1:2 propensity matching. High-throughput sequencing of the gastric mucosal microbiota was performed, and the results were evaluated by alpha diversity analysis, beta diversity analysis, species correlation analysis, and metabolic pathway correlation analysis.
Results: The eradication rate of all the patients was 95.5% (171/179). Twenty-four patients were enrolled in the study after propensity-matched scoring. There were eight cases in the failure group (patients who did not respond well to therapy) and 16 cases in the success group. The majority phyla in the two groups were the same, and included Proteobacteria, Bacteroides, Firmicutes, Actinomycetes, and Fusobacteria. The microbial diversity in the failure group had a decreasing trend (P = 0.092) and the species abundance was significantly lower (P = 0.031) compared with the success group. The high rate of H. pylori eradication was associated with Rhodococcus, Lactobacillus, and Sphingomonas, as they were significantly enriched in the successful group (P < 0.05). Veronococcus and Cilium were enriched in the mucosa of chronic atrophic gastritis patients compared with chronic superficial gastritis patients (P = 0.0466 and 0.0122, respectively). In both study groups, H. pylori was negatively correlated with other bacterial genera. More bacterial genera were directly related to H. pylori in the successful group compared with the failure group.
Conclusion: The effectiveness of quadruple H. pylori eradication therapy containing bismuth depended on gastric microbiota, and the high rate of H. pylori eradication was associated with the presence of Rhodococcus, Lactobacillus, and Sphingomonas.
Keywords: Eradication; Gastric microbiota; Helicobacter pylori; Influence factors; Quadruple therapy; propensity matching.
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors declare that they have no competing interests.
Figures




Similar articles
-
Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.Dig Dis Sci. 2017 Jun;62(6):1580-1589. doi: 10.1007/s10620-017-4564-4. Epub 2017 Apr 8. Dig Dis Sci. 2017. PMID: 28391418 Clinical Trial.
-
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.Helicobacter. 2018 Aug;23(4):e12498. doi: 10.1111/hel.12498. Epub 2018 Jun 13. Helicobacter. 2018. PMID: 29897654
-
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.Dig Liver Dis. 2016 May;48(5):506-511. doi: 10.1016/j.dld.2016.01.002. Epub 2016 Jan 15. Dig Liver Dis. 2016. PMID: 26847964
-
Second-line rescue treatment of Helicobacter pylori infection: Where are we now?World J Gastroenterol. 2018 Oct 28;24(40):4548-4553. doi: 10.3748/wjg.v24.i40.4548. World J Gastroenterol. 2018. PMID: 30386104 Free PMC article. Review.
-
Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28529929 Free PMC article. Review.
Cited by
-
Refractory Helicobacter pylori infection and the gastric microbiota.Front Cell Infect Microbiol. 2022 Sep 27;12:976710. doi: 10.3389/fcimb.2022.976710. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36237432 Free PMC article.
-
Gastrointestinal microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit-risk approach?World J Gastroenterol. 2022 Feb 21;28(7):766-774. doi: 10.3748/wjg.v28.i7.766. World J Gastroenterol. 2022. PMID: 35317277 Free PMC article.
-
Helicobacter pylori and oral-gut microbiome: clinical implications.Infection. 2024 Apr;52(2):289-300. doi: 10.1007/s15010-023-02115-7. Epub 2023 Nov 2. Infection. 2024. PMID: 37917397 Free PMC article. Review.
-
The impact of Helicobacter pylori infection and eradication therapies on gut microbiota: a systematic review of microbial dysbiosis and its implications in gastric carcinogenesis.Front Cell Infect Microbiol. 2025 Jul 7;15:1592977. doi: 10.3389/fcimb.2025.1592977. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40692683 Free PMC article.
-
Gastric microbiota dysbiosis and Helicobacter pylori infection.Front Microbiol. 2023 Mar 30;14:1153269. doi: 10.3389/fmicb.2023.1153269. eCollection 2023. Front Microbiol. 2023. PMID: 37065152 Free PMC article. Review.
References
-
- Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315. - PubMed
-
- Mustapha P, Paris I, Garcia M, Tran CT, Cremniter J, Garnier M, Faure JP, Barthes T, Boneca IG, Morel F, Lecron JC, Burucoa C, Bodet C. Chemokines and antimicrobial peptides have a cag-dependent early response to Helicobacter pylori infection in primary human gastric epithelial cells. Infect Immun. 2014;82:2881–2889. - PMC - PubMed
-
- Yin YN, Wang CL, Liu XW, Cui Y, Xie N, Yu QF, Li FJ, Lu FG. Gastric and duodenum microflora analysis after long-term Helicobacter pylori infection in Mongolian Gerbils. Helicobacter. 2011;16:389–397. - PubMed
-
- Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007;133:659–672. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical